📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $ImmunityBio(IBRX.US) ImmunityBi

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $ImmunityBio(IBRX.US) ImmunityBio Q2 ANKTIVA Revenue Jumps 92% as Regulatory Pipeline Advances

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ Q2 net product revenue reached 𝗦𝟱𝟬.𝟳 𝗺𝗶𝗹𝗹𝗶𝗼𝗻, up 𝟵𝟮%.

➤ Revenue increased 𝟭𝟱% sequentially, marking eight consecutive growth quarters.

➤ First-half product revenue rose 𝟭𝟮𝟭% to 𝗦𝟵𝟰.𝟴 𝗺𝗶𝗹𝗹𝗶𝗼𝗻.

➤ Cash and marketable securities totaled 𝗦𝟯𝟱𝟳.𝟰 𝗺𝗶𝗹𝗹𝗶𝗼𝗻.

➤ FDA set a 𝗝𝗮𝗻𝘂𝗮𝗿𝘆 𝟲, 𝟮𝟬𝟮𝟳 PDUFA date.

➤ UAE authorized 𝗔𝗡𝗞𝗧𝗜𝗩𝗔 across broader bladder and lung cancers.

➤ Q2 adjusted net loss improved to 𝗦𝟴𝟭.𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻.

➤ Reported Q2 net loss widened to 𝗦𝟮𝟯𝟬.𝟰 𝗺𝗶𝗹𝗹𝗶𝗼𝗻.

➤ ImmunityBio secured exclusive U.S. rights to 𝗧𝗼𝗸𝘆𝗼-𝟭𝟳𝟮 𝗕𝗖𝗚.

➤ Multiple regulatory and clinical milestones are expected within 𝟭𝟮 months.

👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:

➤ Strong ANKTIVA growth signals expanding physician adoption and commercial traction.

➤ Broader approvals could significantly expand ImmunityBio’s addressable oncology market.

➤ The January 2027 FDA decision represents a major near-term catalyst.

➤ Improved adjusted losses suggest stronger underlying operating performance.

➤ The large reported loss remains a key financial risk for investors.

👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:

𝗥𝗶𝗰𝗵𝗮𝗿𝗱 𝗔𝗱𝗰𝗼𝗰𝗸, President and CEO of ImmunityBio:

“Our record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKTIVA and disciplined commercial execution,” said Richard Adcock, President and CEO of ImmunityBio. “At the same time, we continue to invest in expanding ANKTIVA’s global commercial footprint while advancing a focused late-stage clinical pipeline that we believe will create additional opportunities across multiple oncology indications. With $357.4 million in cash and cash equivalents, and marketable securities, we are well-positioned to support both our commercial and clinical priorities.”

𝗣𝗮𝘁𝗿𝗶𝗰𝗸 𝗦𝗼𝗼𝗻-𝗦𝗵𝗶𝗼𝗻𝗴, 𝗠.𝗗., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio:

“The continued adoption of ANKTIVA in clinical practice reinforces the potential of our IL-15 receptor agonist platform to activate the body’s natural killer and T cells to fight cancer,” said Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio. “As we continue generating clinical evidence across multiple tumor types, including bladder cancer, lung cancer, and hematologic malignancies, we remain focused on expanding the potential applications of this platform to address additional areas of significant unmet medical need.”